Matinas BioPharma Holdings, Inc. (MTNB) Income Statement
MTNB 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsMTNB revenue and net income
MTNB profit margins
MTNB growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MTNB quarterly EPS vs estimates
Matinas BioPharma beat the analyst EPS estimate in 2 of the last 3 quarters. Next report: November 9, 2026.
MTNB income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.1M | $3.2M | $33,000 | $158,333 | $89,812 | $119,750 | $149,687 | $0 |
| Cost of revenue | $456,000 | $972,000 | $941,000 | $16.7M | $14.6M | $14.4M | $11.2M | $6.8M | $9.0M | $52,644 |
| Gross profit | −$456,000 | −$972,000 | $155,000 | −$13.5M | −$14.6M | −$14.2M | −$11.1M | −$6.7M | −$8.9M | −$52,644 |
| Research & development | $85,000 | $11.4M | $14.5M | $16.7M | $14.6M | $14.4M | $11.2M | $6.8M | $9.0M | $3.9M |
| Sales, general & admin | $6.9M | $7.8M | $9.4M | $11.1M | $10.2M | $10.0M | $7.8M | $8.0M | $7.6M | $4.3M |
| Total operating expenses | $6.5M | $19.2M | $23.9M | $11.1M | $10.2M | $10.0M | $7.8M | $14.8M | $16.7M | $8.3M |
| Operating income | −$7.0M | −$20.2M | −$23.8M | −$24.6M | −$24.7M | −$24.2M | −$18.9M | −$14.6M | −$16.5M | −$8.3M |
| Interest income | — | — | — | — | — | — | $541,300 | $56,550 | $22,030 | $16,510 |
| Interest expense | — | — | — | $3.6M | $1.5M | $0 | $0 | $0 | $0 | $0 |
| Income before taxes | −$10.3M | −$24.3M | −$22.9M | −$21.0M | −$23.3M | −$22.4M | −$17.4M | −$14.6M | −$15.8M | −$7.6M |
| Income taxes | — | −$80,000 | $773,105 | −$8.0M | −$2.1M | −$1.8M | −$1.8M | −$506,920 | −$356,956 | −$674,901 |
| Net income | −$10.3M | −$24.3M | −$22.9M | −$21.0M | −$23.3M | −$22.4M | −$17.4M | −$14.1M | −$15.5M | −$7.6M |
| EBITDA | −$9.9M | −$19.2M | −$22.0M | −$20.1M | −$22.5M | −$23.4M | −$18.1M | −$14.4M | −$16.4M | −$8.2M |
| EPS (diluted) | −$6.24 | −$3.18 | −$4.52 | −$4.52 | −$4.03 | −$3.06 | −$6.93 | −$6.03 | −$16.54 | −$5.60 |
| Gross margin | — | — | 14.1% | −423.1% | −44,090.9% | −8,968.8% | −12,409.0% | −5,568.0% | −5,919.6% | — |
| Operating margin | — | — | −2,168.4% | −771.3% | −74,954.5% | −15,288.4% | −21,067.4% | −12,230.9% | −11,024.6% | — |
| Net margin | — | — | −2,093.2% | −658.6% | −70,554.5% | −14,177.0% | −19,343.4% | −11,760.4% | −10,345.9% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $962,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $4,000 | $74,000 | −$85,000 | $114,000 | $124,000 | $85,000 | — | $2.2M | $3.4M | $240,000 | $3.7M | $3.3M |
| Gross profit | −$4,000 | −$74,000 | $85,000 | −$114,000 | −$124,000 | −$85,000 | — | −$2.2M | −$3.4M | −$240,000 | −$3.7M | −$3.3M |
| Research & development | $0 | $0 | $0 | $0 | $0 | $85,000 | $2.4M | $2.2M | $3.4M | $3.4M | $3.7M | $3.3M |
| Sales, general & admin | $1.6M | $1.9M | $1.6M | $1.5M | $1.7M | $1.9M | $1.7M | $2.1M | $2.5M | $2.5M | $2.2M | $2.8M |
| Total operating expenses | $1.6M | $1.9M | $1.7M | $1.5M | $1.7M | $1.9M | $4.0M | $2.1M | $2.5M | $5.7M | $2.2M | $2.8M |
| Operating income | −$1.6M | −$1.9M | −$1.6M | −$1.6M | −$1.8M | −$1.9M | −$4.0M | −$4.4M | −$5.8M | −$5.9M | −$5.9M | −$6.1M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $73,000 | — |
| Income before taxes | −$1.3M | −$1.9M | −$1.9M | −$2.1M | −$5.2M | −$1.7M | −$8.5M | −$4.3M | −$5.7M | −$5.8M | −$5.3M | −$6.1M |
| Income taxes | — | — | — | — | — | −$80,000 | — | — | — | $196,724 | $311,000 | −$238,000 |
| Net income | −$1.3M | −$1.9M | −$1.9M | −$2.1M | −$5.2M | −$1.7M | −$8.4M | −$4.3M | −$5.7M | −$5.8M | −$5.3M | −$6.1M |
| EBITDA | −$1.8M | −$1.8M | −$604,000 | −$2.0M | −$5.1M | −$1.5M | — | −$4.0M | −$5.5M | −$5.6M | −$5.1M | −$5.8M |
| EPS (diluted) | −$0.21 | −$0.30 | −$4.48 | −$0.40 | −$1.03 | −$0.33 | −$0.81 | −$0.85 | −$0.02 | −$1.50 | −$0.02 | −$1.50 |
| Gross margin | — | — | — | — | — | −8.8% | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | −202.3% | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | −172.1% | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MTNB's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MTNB financial results
Matinas BioPharma reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $10.3 million. Diluted earnings per share came to −$6.24.
See the MTNB stock overview for the latest quote and news, or the MTNB chart for price history and technical indicators.
MTNB income statement FAQ
Does Matinas BioPharma have revenue?
Matinas BioPharma reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Matinas BioPharma profitable?
No. Matinas BioPharma reported a net loss of $10.3 million in fiscal 2025.
How much does Matinas BioPharma spend on research and development?
Matinas BioPharma spent $0.1 million on research and development in fiscal 2025.
What are Matinas BioPharma's earnings per share?
Matinas BioPharma earned $-6.24 per diluted share in fiscal 2025, compared with $-3.18 a year earlier.
When will Matinas BioPharma report its next earnings?
Matinas BioPharma is expected to report results for the quarter ending September 30, 2026 on November 9, 2026.
When does Matinas BioPharma's fiscal year end?
Matinas BioPharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.